

ASX Announcement

8 December 2023

Another milestone delivered in the OncoSil™ device's commercialisation strategy

First two commercial patient treatments in Greece

Melbourne, Australia – 8 December 2023: OncoSil Medical Ltd (ASX: OSL) (“OncoSil” or “the Company”), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), announces;

The first Initial commercial treatments involving the OncoSil™ device in Greece have just commenced at renowned hospital in Athens.

Key Highlights

- The first two patient treatments in Greece using the OncoSil™ device occurred on Thursday, 7 December 2023.
- These treatments see Greece become the third European country – after Italy and Spain – where commercial treatments utilising the OncoSil™ device have been completed.
- The treatments involved two patients in the care of Agios Savvas Hospital, located in Athens.

These treatments represent delivery of another milestone in the commercialisation strategy for this innovative device, which is intended for the treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.

In cooperation with our Greek partners Mediray , these treatments see Greece becoming the third European country – after Italy and Spain (announced on 22 May 2023 and 13 April 2022 respectively) – where commercial treatments utilising the OncoSil™ device have been ongoing.

Another milestone achieved in the OncoSil™ device’s commercialisation strategy

The first commercial treatments on Greece-based patients with locally advanced pancreatic cancer represent another step in OncoSil’s plans to penetrate its target European market, which extends across multiple countries. As these treatments are commercial rather than clinical trial related, they additionally represent a clear positive signal for OncoSil’s long-term sustainability.

These treatments, which involved two patients, were undertaken at the Agios Savvas Hospital, located in Athens. This facility specialises in the treatment of all solid tumors, with a primary emphasis on breast, lung, digestive, pancreatic and melanoma cancers.

OncoSil Medical CEO & Managing Director Nigel Lange said: *“It is good to see the continued progress being made in our concerted efforts to commercialise the OncoSil™ device. The just-completed initial commercial treatments in Greece at the Agios Savvas Hospital means that our innovative OncoSil™ device has now been utilised in commercial treatments in three European countries – and we remain confident that other countries across Western Europe will join this list.”*

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 16096424981</p>	<p>Mr. Christian Dal Cin The CFO Solution CFO & Company Secretary E: christian@thecfo.com.au T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
---	---	---

About OncoSil

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.